Combination therapy of a GLP-1/GIP medication (tirzepatide) to lessen the side effects from a pure GLP-1 receptor agonist
While some people may start to see weight loss and other benefits early on, others may need a bit more time
Currently, there is insufficient evidence to support the use of GLP-1 in treating binge eating disorder, but some studies suggest it may be helpful.18 Ongoing assessment and open discussions about the risks are recommended for this population.19 Clinical Efficacy: Weight Management, Type 2 Diabetes, and Cardiovascular Protection Weight Management Weight loss remains a primary reason individuals begin GLP-1 medications, and the STEP clinical trial program has been instrumental in evaluating the efficacy of semaglutide 2.4 mg for chronic weight management across diverse populations, with study participants recruited from a wide range of countries
Combined with the convenience of at-home initiation and ongoing virtual care, MEDVi offers a revolutionary shift in how weight loss is delivered and sustained in the digital age
Nothing shifted, nothing was loose, and the vial was intact on arrival